News | May 29, 2023
Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Product deliveries scheduled in Q3 of 2023
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
This is the second US FDA GMP inspection of this facility within one year
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Subscribe To Our Newsletter & Stay Updated
